Navigation Links
NeoGenomics Files Annual Report on Form 10-KSB with the SEC

Also Announces Change to Unaudited Financial Results Released March 18,


FT. MYERS, Fla., April 15 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it had filed with the Securities and Exchange Commission its annual report on Form 10-KSB for the year ended December 31, 2007. A copy of this annual report can be found at .

The audited financial statements for the year ended December 31, 2007 included in the 10-KSB included an additional contingency charge expense of approximately $177,000 versus the unaudited results we issued on March 18, 2008. This contingency charge was for registration penalties we have been incurring as a result of delays in completing an effective registration statement for the shares we sold in our June 2007 private placement. In accordance with FASB Staff Position 00-19-2, "Accounting for Registration Payment Arrangements", we have accrued approximately $177,000 of penalty expense as of December 31, 2007 for the liquidated damages expected through May 2008. As a result of this change, our audited net loss for FY 2007 has increased by $177,000 versus the net loss we issued in our March 18, 2008 earnings release. However, by taking a charge for this in 2007, we hope to avoid any further negative impacts to our income statement from these penalties in 2008.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and select reference laboratories throughout the United States. For additional information about NeoGenomics, visit .

Interested parties can also access additional investor relations material from the American Microcap Institute at or from Hawk Associates at . An investment profile about NeoGenomics may be found at .

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
5. Arrow International Files and Mails Definitive Proxy Materials
6. VaxGen Files 2006 Financial Statements and Provides Cash Update
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Anacor Files Registration Statement for Initial Public Offering
9. IsoTis Files Definitive Proxy Statement
10. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
11. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):